Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis

NCT01384630 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
8
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Janssen Research & Development, LLC